Comprehensive Biochemistry: Metabolic Regulation, Carbohydrates, and Ethanol Metabolism

• Canvas Quizzes and Review Sessions:

  • 
    

Overview of Hormonal Regulation and Metabolic Homeostasis

• Integration of Fuel Utilization:

  • Metabolic homeostasis relies on inter-tissue communication to balance fuel storage and mobilization according to supply and demand.

  • Circulating blood concentrations of nutrients dictate tissue rates of storage or utilization.

  • Excess Fuel Storage: Surplus nutrients are stored primarily as triacylglycerols (fatty acids in adipose tissue) and glycogen (in the liver and skeletal muscle).

  • Neural and Endocrine Regulation: Hormones transport biochemical signals between peripheral tissues; the central nervous system uses direct neural signaling and neuroendocrine pathways to regulate tissue metabolism.

• Key Regulatory Hormones:

  • Insulin: The principal anabolic hormone of the body. Released in response to elevated blood nutrients to promote cellular nutrient uptake, glycogen synthesis, lipogenesis, and protein synthesis.

  • Glucagon: The primary catabolic fuel-mobilization hormone. Released during nutrient deprivation to stimulate hepatic glycogenolysis, gluconeogenesis, and lipolysis.

  • Epinephrine & Norepinephrine: Stress hormones released during fight-or-flight responses via the sympathetic nervous system to rapidly mobilize stored energy.

  • Cortisol & ACTH: Released via the Hypothalamic-Pituitary-Adrenal (HPA) axis during sustained physiological stress to maintain blood glucose levels.

• Systemic Glucose Homeostasis:

  • Normal physiological fasting blood glucose is maintained within a tight range of $80-100\,mg/dL$.

  • Continuous Glucose Demands:

    • Brain & Central Nervous System: Requires a continuous glucose supply because fatty acids cannot cross the blood-brain barrier. Uses ketone bodies during prolonged starvation, but prefers glucose above all else.

    • Red Blood Cells (Erythrocytes): Entirely dependent on glucose and anaerobic glycolysis due to a complete lack of mitochondria.

    • Skeletal Muscle: Requires high glucose flux during exertion.

Pancreatic Islet Architecture and Islet Cell Function

• Islets of Langerhans Structure:

  • The endocrine pancreas consists of microscopic cell clusters called Islets of Langerhans embedded within exocrine tissue.

  • Cell Types: Composed primarily of $\beta$ cells (secrete insulin) and $\text{alpha}$ cells (secrete glucagon).

  • Vascularization: Islets are densely vascularized with capillaries directly adjacent to endocrine cells.

  • Physiological Significance of Islet Architecture:

    1. Allows rapid, continuous monitoring of arterial blood glucose concentrations.

    2. Facilitates immediate, direct systemic secretion of insulin and glucagon into the blood.

Insulin: Synthesis, Processing, and Secretion Mechanisms

• Structure and Peptide Processing:

  • Active insulin consists of two polypeptide chains ($A$ chain and $B$ chain) linked together by interchain disulfide bridges ($-S-S-$).

  • Biosynthetic Steps:

    1. Preproinsulin: Translated on the rough endoplasmic reticulum (RER).

    2. Proinsulin: Cleaved in the ER lumen and routed to the Golgi apparatus. Proinsulin contains the $A$ chain, $B$ chain, and an intervening $C$-peptide (connecting peptide).

    3. Proteolytic Cleavage: Proteases in Golgi secretory granules cleave the $C$-peptide at specific dibasic amino acid residues.

    4. Granule Packaging: Active insulin ($A$ and $B$ chains) co-precipitates with zinc ions ($Zn^{2+}$) into dense-core secretory granules alongside free $C$-peptide.

• Stimulus-Secretion Coupling in Pancreatic $\beta$ Cells:

  1. Glucose Entry: Circulating glucose enters $\beta$ cells down its concentration gradient via high-capacity, low-affinity GLUT2 transporters.

  2. Phosphorylation: Glucokinase (Hexokinase IV) phosphorylates glucose to Glucose-6-Phosphate (G6P).

  3. ATP Generation: G6P undergoes glycolysis, the TCA cycle, and oxidative phosphorylation, significantly raising the intracellular $\text{ATP}/\text{ADP}$ ratio.

  4. Channel Closure: Elevated ATP binds to and closes ATP-dependent potassium channels ($K_{ATP}$) on the plasma membrane, preventing $K^+$ efflux.

  5. Depolarization: Closure of $K_{ATP}$ channels depolarizes the $\beta$-cell plasma membrane.

  6. Calcium Influx: Membrane depolarization opens voltage-gated calcium channels ($Ca_{v}$), leading to a rapid influx of extracellular calcium ($Ca^{2+}$).

  7. Exocytosis: Intracellular $Ca^{2+}$ elevation triggers exocytosis of mature insulin granules, releasing insulin and $C$-peptide into the bloodstream in a 1:1 molar ratio.

• Endocrine and Autonomic Modulators of Insulin Secretion:

  • Incretins: Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Peptide (GIP) bind GPCRs on $\beta$ cells, stimulating adenylyl cyclase, raising cAMP, elevating $Ca^{2+}$, and potentiating glucose-dependent insulin secretion. GLP-1 also suppresses appetite and causes nausea.

  • Epinephrine: Inhibits insulin secretion via $\text{alpha}_2$-adrenergic receptors to ensure energy mobilization during fight-or-flight responses.

Insulin Receptor Signaling Pathways

• Insulin Receptor Structure:

  • A heterotetrameric receptor tyrosine kinase composed of two extracellular $\text{alpha}$ subunits and two transmembrane $\beta$ subunits linked by disulfide bonds.

  • Insulin binds to the extracellular $\text{alpha}$ subunits, inducing receptor dimerization, conformational changes, and autophosphorylation of tyrosine residues on the intracellular $\beta$ subunits.

• Intracellular Cascade:

  1. Phosphorylated tyrosine residues recruit and phosphorylate Insulin Receptor Substrate (IRS) proteins.

  2. Activated IRS stimulates Phosphoinositide 3-Kinase (PI3K).

  3. PI3K generates $PIP_3$, activating Protein Kinase B (AKT) and downstream mTOR signaling cascades.

• Translocation of GLUT4:

  • AKT activation promotes exocytosis of intracellular vesicles containing GLUT4 (the insulin-sensitive glucose transporter) to the plasma membrane.

  • GLUT4 insertion dramatically increases glucose clearance from the blood into skeletal muscle and adipose tissue.

• Pleiotropic Metabolic Effects:

  • Reverses glucagon-mediated phosphorylation events via activation of protein phosphatases.

  • Promotes gene transcription and translation for anabolic enzymes while suppressing catabolic enzyme synthesis.

  • Functions as a growth factor through the Ras/MAPK signaling cascade.

Glucagon: Synthesis, Secretion, and GPCR Signaling

• Synthesis and Half-Life:

  • Synthesized in pancreatic $\text{alpha}$ cells as proglucagon (a $160$-amino-acid precursor) and cleaved into a mature $29$-amino-acid peptide.

  • Plasma Half-Life: Rapidly cleared with a half-life of $3-5\text{ minutes}$. Rapid degradation prevents sustained hyper-glycemic responses and allows precise control of blood glucose.

• Regulation of Secretion:

  • Inhibited by: Elevated blood glucose and high insulin levels.

  • Stimulated by: Decreased blood glucose, epinephrine, and high protein/amino acid meals (e.g., a steak meal raises amino acids, triggering glucagon to facilitate gluconeogenesis and amino acid nitrogen clearance).

• Intracellular Signaling Mechanism:

  1. Glucagon binds to a cell-surface 7-transmembrane G-Protein Coupled Receptor (GPCR) on hepatocytes.

  2. Binds and activates the stimulatory G-protein subunit ($G_{\text{alpha}s}$), causing GDP-GTP exchange.

  3. $G_{\text{alpha}s}$ activates Adenylyl Cyclase, converting ATP to cyclic AMP (cAMP).

  4. cAMP binds to and activates Protein Kinase A (PKA).

  5. PKA phosphorylates key metabolic enzymes (e.g., phosphorylase kinase, glycogen synthase) to activate glycogen breakdown and halt glycogen synthesis.

  6. Signal Termination: cAMP is degraded to AMP by Phosphodiesterase (PDE) enzymes.

  7. Pharmacology Note (PDE Inhibitors): Sildenafil (Viagra) is a PDE5 inhibitor originally developed by Pfizer for cardiovascular disease and coronary artery disease. During clinical trials with older male participants, the unexpected side effect was identified when male subjects refused to return unused study drug.

Epinephrine and Adrenergic Receptor Signaling

• Adrenergic Receptors:

  • Epinephrine binds to $\text{alpha}$- and $\beta$-adrenergic GPCRs.

  • $\beta_2$-Adrenergic Receptors: Located on hepatocytes and skeletal muscle cells; couple to $G_s$ proteins, triggering the Adenylyl Cyclase/cAMP/PKA pathway (identical downstream target activation as glucagon).

  • $\text{alpha}_1$-Adrenergic Receptors: Coupled to $G_q$ proteins; activate Phospholipase C (PLC) to produce Inositol 1,4,5-trisphosphate ($IP_3$) and Diacylglycerol (DAG).

• $IP_3$/Calcium Signaling:

  • $IP_3$ binds to receptors on the endoplasmic/sarcoplasmic reticulum, triggering a rapid release of stored intracellular calcium ($Ca^{2+}$).

  • Free $Ca^{2+}$ binds Calmodulin, forming a $Ca^{2+}$-Calmodulin complex that directly activates Calmodulin-dependent protein kinases and Phosphorylase Kinase, accelerating glycogen degradation.

Dietary Carbohydrates and Digestive Glycosidases

• Dietary Carbohydrate Structures:

  • Amylose: Linear plant starch consisting of glucose residues connected exclusively by $\text{alpha}-1,4$ glycosidic bonds.

  • Amylopectin: Branched plant starch containing linear $\text{alpha}-1,4$ glucose chains with $\text{alpha}-1,6$ glycosidic branch points.

  • Sucrose: Disaccharide composed of glucose and fructose linked by an $\text{alpha}-1,2$ glycosidic bond.

  • Lactose: Disaccharide found in dairy consisting of galactose and glucose connected by a $\beta-1,4$ glycosidic bond.

  • Dietary Fiber: Indigestible plant polysaccharides (e.g., cellulose) containing linkages for which humans lack hydrolytic enzymes.

  • Dietary Requirement: Glucose is essential for metabolic energy production, but glucose itself is not an essential dietary nutrient because the human body can synthesize it endogenously via gluconeogenesis from amino acids, glycerol, and lactate.

• Digestive Glycosidases and Processing Steps:

  1. Salivary $\text{alpha}$-Amylase: An endoglucosidase secreted in saliva that hydrolyzes internal $\text{alpha}-1,4$ glycosidic bonds randomly within starches, producing short, random-length branched and linear oligosaccharides called $\text{alpha}$-dextrins.

  2. Gastric Phase: Salivary amylase is denatured and inactivated by acidic stomach pH ($\sim 2$).

  3. Pancreatic Phase: The pancreas secretes pancreatic $\text{alpha}$-amylase along with bicarbonate ($HCO_3^-$) into the duodenum. Bicarbonate neutralizes stomach acid, restoring pH to an optimal range for pancreatic $\text{alpha}$-amylase to continue hydrolyzing internal $\text{alpha}-1,4$ bonds. Pancreatic $\text{alpha}$-amylase cannot cleave $\text{alpha}-1,6$ branch points or terminal linkages.

  4. Intestinal Brush Border Glycosidases:

     • Glucoamylase (Maltase-Glucoamylase): Membrane-bound exoglucosidase that cleaves external $\text{alpha}-1,4$ bonds sequentially from the non-reducing end of oligosaccharides, releasing single free glucose molecules.

     • Sucrase-Isomaltase Complex: Dual-function enzyme. The isomaltase domain hydrolyzes $\text{alpha}-1,6$ glycosidic bonds at branch points (e.g., isomaltose). The sucrase domain provides $100\%$ of the intestinal capacity to hydrolyze sucrose into glucose and fructose.

     • Trehalase: Hydrolyzes the specific $\text{alpha}-1,1$ glycosidic bond found in trehalose (a sugar present in mushrooms and insects). Deficiency causes severe gastrointestinal distress upon consuming mushrooms.

     • Lactase ($\beta$-Galactosidase Complex): Brush border glycoprotein that hydrolyzes the $\beta-1,4$ glycosidic bond of lactose into free galactose and glucose.

• Lactose Intolerance:

  • Etiology: Low levels of brush border lactase or intestinal mucosal injury (lactase is the first enzyme lost during enterocyte damage and the last to recover).

  • Developmental Pattern: Highest in infants to facilitate milk digestion; enzyme expression declines post-weaning (by age $7-8$) to normal adult levels in a majority of the global human population.

  • Pathophysiology: Unabsorbed lactose remains in the intestinal lumen, creating an osmotic gradient that draws water into the bowel (causing osmotic diarrhea). Colonic bacteria ferment undigested lactose into short-chain fatty acids, lactic acid, and gases ($CO_2$, $H_2$), resulting in flatulence, abdominal cramps, and gut distension.

Intestinal Absorption and Transport of Monosaccharides

• Monosaccharide Uptake Mechanics:

  • Polar monosaccharides cannot cross lipid bilayers by simple diffusion.

  • Apical Transporters (Intestinal Lumen into Enterocyte):

    • SGLT1 (Sodium-Glucose Cotransporter 1): Secondary active transporter that co-transports $1$ glucose or galactose molecule alongside $2-3$ $Na^+$ ions down the sodium concentration gradient.

    • $Na^+/K^+$ ATPase: Located on the basolateral membrane; pumps $3\text{ Na}^+$ out and $2\text{ K}^+$ into the cell using ATP to maintain the low intracellular sodium gradient driving SGLT1.

    • GLUT5: Facilitated diffusion transporter located on the apical membrane specific for fructose absorption (does not transport glucose).

  • Basolateral Transporter (Enterocyte into Bloodstream):

    • GLUT2: High-capacity facilitated diffusion transporter that moves glucose, galactose, and fructose across the basolateral membrane into systemic circulation.

Glucose Transporter (GLUT) Family Kinetics and Tissue Distribution

• All GLUT family members are Solute Carrier (SLC) class membrane proteins containing $12$ transmembrane-spanning domains.

Blood-Brain Barrier and Central Nervous System Glucose Transport

• Blood-Brain Barrier (BBB) Architecture:

  • Capillaries in the central nervous system feature continuous tight junctions between endothelial cells, preventing paracellular diffusion of polar molecules.

• Sequential Transport Cascade:

  1. Capillary Entry: Glucose in blood is transported across the luminal endothelial membrane into endothelial cells via high-affinity GLUT1 transporters.

  2. Interstitial Release: Transported across the abluminal membrane via GLUT1 into the extracellular space/cerebrospinal fluid (CSF).

  3. Neuronal Uptake: Neurons rapidly import glucose from interstitial fluid using high-affinity GLUT3 transporters.

• Clinical Consequences of Hypoglycemia:

  • When arterial blood glucose drops below critical thresholds, the rate of brain glucose transport falls below the rate of neuronal brain glucose metabolism.

  • CNS Symptoms: Lightheadedness, dizziness, confusion, lethargy, loss of consciousness/syncope, seizures, and coma.

  • Clinical Example: A public collapse involving the Prime Minister of Sweden (a Type 1 diabetic) occurred due to severe acute hypoglycemia and CNS glucose deprivation after missed meal intake.

Glycogen Structure, Function, and Tissue-Specific Roles

• Molecular Architecture of Glycogen:

  • A massive, hyper-branched spherical polymer composed exclusively of $\text{alpha}$- ext{D}-glucose residues.

  • Linear Chains: Formed by $\text{alpha}-1,4$ glycosidic linkages.

  • Branch Points: Formed by $\text{alpha}-1,6$ glycosidic linkages occurring every $8-12$ glucose residues.

  • Core Protein: Glycogenin, a self-glucosylation enzyme/protein dimer located at the structural center of each glycogen molecule that acts as the obligate primer.

  • Advantages of Branching:

    1. Compact space-saving storage of tens of thousands of glucose units.

    2. Increases water solubility.

    3. Creates vast numbers of non-reducing terminal ends, allowing simultaneous rapid enzymatic synthesis and degradation.

• Tissue-Specific Physiological Roles:

  • Skeletal Muscle Glycogen:

    • Functions strictly as an intracellular glucose reserve for generating ATP via glycolysis within the muscle cell during mechanical contraction.

    • Lack of Systemic Export: Skeletal muscle lacks the enzyme Glucose-6-Phosphatase. Therefore, muscle glycogen cannot be released into the blood to regulate systemic blood glucose.

    • Lactate Generation: During anaerobic contraction, muscle converts glycogen to lactate, which enters the blood and undergoes gluconeogenesis in the liver (Cori Cycle).

  • Liver Glycogen:

    • Serves as the primary immediate systemic reservoir to maintain blood glucose homeostasis during early fasting.

    • Liver glycogen stores are significantly depleted within $4\text{ hours}$ of fasting.

Glycogenesis: Pathway and Enzymatic Steps

1. Glucose Trapping: Glucose entering hepatocytes via GLUT2 is phosphorylated to Glucose-6-Phosphate (G6P) by Glucokinase (Hexokinase IV), consuming $1\text{ ATP}$.

2. Isomerization: Phosphoglucomutase reversibly converts G6P to Glucose-1-Phosphate (G1P).

3. Activation (UDP-Glucose Synthesis):

   • $\text{G1P} + \text{UTP} \rightleftharpoons \text{UDP-Glucose} + PP_i$ (catalyzed by UDP-Glucose Pyrophosphorylase).

   • Inorganic pyrophosphatase rapidly hydrolyzes $PP_i \rightarrow 2\,P_i$, pulling the reaction irreversibly forward.

   • UDP-Glucose serves as the active donor substrate for glycogen assembly.

4. Chain Elongation: Glycogen Synthase transfers the glucose moiety from UDP-Glucose to the non-reducing end of an existing glycogen chain, forming an $\text{alpha}-1,4$ glycosidic bond and releasing UDP.

5. Branch Formation: Branching Enzyme ($4,6$-transferase or amylo-$\text{alpha}-1,4 \rightarrow 1,6$-transglucosidase) cleaves a terminal chain of $\sim 6-8$ glucose residues containing an $\text{alpha}-1,4$ bond and transfers it to the C6 hydroxyl group of an internal glucose residue, creating an $\text{alpha}-1,6$ branch point.

Glycogenolysis: Pathway and Enzymatic Steps

1. Phosphorolytic Cleavage: Glycogen Phosphorylase uses inorganic phosphate ($P_i$) to cleave terminal $\text{alpha}-1,4$ glycosidic bonds from non-reducing ends, yielding Glucose-1-Phosphate (G1P). This step conserves energy by avoiding ATP consumption.

2. Steric Limitation: Glycogen phosphorylase stops cleaving when it reaches a distance of $4$ glucose residues away from an $\text{alpha}-1,6$ branch point (the limit dextrin).

3. Debranching Bifunctional Processing:

   • $4,4$ Transferase Activity: Oligo-$\text{alpha}-1,4 \rightarrow 1,4$-Glucan Transferase cleaves an outer trisaccharide unit from the branch and attaches it to the non-reducing end of a main linear chain via an $\text{alpha}-1,4$ bond.

   • $\text{alpha}-1,6$ Glucosidase Activity: The remaining single glucose residue attached at the $\text{alpha}-1,6$ branch point is cleaved hydrolytically by $\text{alpha}-1,6$-Glucosidase, releasing $1$ free glucose molecule (not G1P).

4. Conversion to Exportable Glucose:

   • Phosphoglucomutase converts G1P to G6P.

   • In the liver, G6P enters the endoplasmic reticulum lumen, where Glucose-6-Phosphatase cleaves the phosphate, generating free Glucose.

   • Free glucose exits hepatocytes into the blood via GLUT2 to raise systemic blood glucose levels.

Hormonal and Allosteric Regulation of Glycogen Metabolism

• Hepatic Hormonal Control (Glucagon and Epinephrine vs. Insulin):

  • Fasting / Stress (Glucagon / Epinephrine):

    • Bind GPCRs $\rightarrow$ $G_s$ $\rightarrow$ Adenylyl Cyclase $\rightarrow$ cAMP $\rightarrow$ Protein Kinase A (PKA) activation.

    • PKA phosphorylates Phosphorylase Kinase (activating it).

    • Active Phosphorylase Kinase phosphorylates Glycogen Phosphorylase (converting inactive 'b' form to active 'a' form), stimulating glycogen breakdown.

    • PKA simultaneously phosphorylates Glycogen Synthase (inactivating it), shutting down glycogen synthesis.

  • Fed State (Insulin):

    • Binds Insulin Receptor $\rightarrow$ activates Hepatic Protein Phosphatase 1 (PP1).

    • PP1 dephosphorylates Glycogen Synthase (activating it).

    • PP1 dephosphorylates Glycogen Phosphorylase and Phosphorylase Kinase (inactivating them), halting breakdown and promoting storage.

• Skeletal Muscle Regulation:

  • Skeletal muscle lacks glucagon receptors; it responds to epinephrine, intracellular calcium, and AMP.

  • Epinephrine: $\beta_2$ receptors increase cAMP/PKA; $\text{alpha}_1$ receptors stimulate PLC/$IP_3$ to release $Ca^{2+}$ from the sarcoplasmic reticulum.

  • Calcium Control: $Ca^{2+}$ binds Calmodulin, forming $Ca^{2+}$-Calmodulin which directly activates Phosphorylase Kinase (without requiring PKA phosphorylation) and Calmodulin-dependent protein kinase (inactivating glycogen synthase).

  • Allosteric AMP Control: Elevated intracellular AMP (signaling low ATP state from exertion) directly binds and activates Glycogen Phosphorylase b without needing phosphorylation.

Neonatal Glycogen Dynamics and Hypoglycemia

• Developmental Physiology:

  • During the final $9-10\text{ weeks}$ of gestation (third trimester), the human fetus rapidly accumulates significant liver glycogen stores derived from maternal placental glucose transfer.

  • At birth, placental glucose supply abruptly terminates, triggering an immediate surge in neonatal glucagon and a spike in liver glycogenolysis to supply systemic glucose until neonatal feeding begins.

• Clinical Presentation (Baby Gretchen Case Study):

  • History: Born at $38\text{ weeks}$ gestation. Mother suffered a severe viral infection with prolonged loss of appetite and severe nausea during the final month of pregnancy, causing maternal malnutrition.

  • Presentation at Delivery: Infant was born cyanotic, limp, with fetal bradycardia during contractions, low Apgar scores, requiring artificial ventilation.

  • Physical Exam: Severely malnourished, thin, hypothermic, heart rate rapid, tachypneic (respiratory rate $55\text{ breaths/min}$).

  • Diagnosis: Severe Neonatal Hypoglycemia caused by failure to accumulate liver glycogen stores during the third trimester due to maternal intrauterine malnutrition.

Fructose Metabolism and the Polyol Pathway

• Hepatic Fructose Utilization:

  1. Fructose is absorbed via GLUT5 and transported to the liver.

  2. Fructokinase phosphorylates fructose to Fructose-1-Phosphate (F1P), consuming $1\text{ ATP}$.

  3. Aldolase B (the rate-limiting enzyme of fructose metabolism) cleaves F1P into Dihydroxyacetone Phosphate (DHAP) and Glyceraldehyde.

  4. Triose Kinase phosphorylates Glyceraldehyde to Glyceraldehyde-3-Phosphate (G3P), consuming $1\text{ ATP}$.

  5. Both DHAP and G3P bypass the primary regulated glycolytic checkpoint (Phosphofructokinase-1 / PFK-1) and enter glycolysis directly.

  • Aldolase Isoenzymes: Aldolase A (muscle), Aldolase B (liver/kidney), Aldolase C (brain). Aldolase B has a much lower affinity for F1P than for Fructose-1,6-bisphosphate.

• The Polyol Pathway (Sorbitol Synthesis):

  • An alternative pathway that converts Glucose to Fructose via a sugar alcohol intermediate:         $\text{Glucose} + \text{NADPH} + \text{H}^+ \xrightarrow{\text{Aldose Reductase}} \text{Sorbitol} + \text{NADP}^+$         $\text{Sorbitol} + \text{NAD}^+ \xrightarrow{\text{Sorbitol Dehydrogenase}} \text{Fructose} + \text{NADH} + \text{H}^+$

  • Pathophysiology in Diabetes: In chronic hyperglycemia, tissues lacking insulin-dependent glucose uptake (lens of eye, retina, peripheral nerves, renal glomeruli) absorb massive quantities of glucose. Aldose Reductase converts excess glucose into Sorbitol. Sorbitol Dehydrogenase is low or absent in the lens, causing Sorbitol to accumulate intracellularly. Sorbitol cannot cross cell membranes, creating an osmotic gradient that draws water into cells, causing swelling, tissue injury, cataracts, elevated intraocular pressure (Glaucoma), and diabetic neuropathy.

Galactose Metabolism

• Hepatic Processing Pathway:

  1. Galactokinase phosphorylates dietary galactose (from lactose) to Galactose-1-Phosphate (Gal-1-P), consuming $1\text{ ATP}$.

  2. Galactose-1-Phosphate Uridylyltransferase (GALT) transfers UDP from UDP-Glucose to Gal-1-P, producing Glucose-1-Phosphate and UDP-Galactose.

  3. UDP-Galactose 4-Epimerase converts UDP-Galactose back into UDP-Glucose.

  • Net Reaction: $\text{Galactose} + \text{ATP} \rightarrow \text{Glucose-1-Phosphate} + \text{ADP}$.

  • Glucose-1-Phosphate is converted to G6P by Phosphoglucomutase to enter glycolysis or glycogenesis.

Pentose Phosphate Pathway (HMP Shunt)

• Location and Functions:

  • Occurs in the cytosol.

  • Primary Objectives: Generates NADPH for reductive biosyntheses and cellular detoxification, and produces Ribose-5-Phosphate for nucleotide, RNA, and DNA synthesis.

• Phase 1: Oxidative Phase (Irreversible):

  1. Glucose-6-Phosphate Dehydrogenase (G6PD) (the rate-limiting enzyme) oxidizes G6P to 6-Phosphoglucono-$\delta$-lactone, generating the $1^{\text{st}}$ mole of NADPH.

  2. Gluconolactonase hydrolyzes 6-Phosphoglucono-$\delta$-lactone to 6-Phosphogluconate.

  3. 6-Phosphogluconate Dehydrogenase oxidizes and decarboxylates 6-Phosphogluconate to Ribulose-5-Phosphate, releasing $1\text{ CO}_2$ and generating the $2^{\text{nd}}$ mole of NADPH.

  • Net Yield per G6P: $2\text{ NADPH}$, $1\text{ CO}_2$, and $1\text{ Ribulose-5-Phosphate}$.

• Phase 2: Non-Oxidative Phase (Reversible):

  • Ribulose-5-Phosphate is converted to Ribose-5-Phosphate (via Isomerase) or Xylulose-5-Phosphate (via Epimerase).

  • Transketolase (requires Thiamine Pyrophosphate / TPP / Vitamin $B_1$ as a cofactor) and Transaldolase interconvert pentose phosphates with glycolytic intermediates (Fructose-6-Phosphate and Glyceraldehyde-3-Phosphate).

  • Reversibility: If the cell requires nucleotides, glycolytic intermediates reverse through this pathway to produce Ribose-5-Phosphate without running the oxidative phase. If the cell requires NADPH, pentose products are recycled back to glycolytic intermediates to continuously feed G6P back into the oxidative phase.

Cellular Antioxidant Defense and Cytochrome P450 Detoxification

• Neutralization of Reactive Oxygen Species (ROS):

  • Electron transport chain leakage and enzymatic reactions generate dangerous ROS, including superoxide radicals ($O_2^{\bullet-}$) and hydrogen peroxide ($H_2O_2$).

  • Glutathione Peroxidase reduces toxic $H_2O_2$ into harmless $H_2O$ by oxidizing reduced monomeric Glutathione (GSH) into Glutathione Disulfide (GSSG).

  • Glutathione Reductase uses NADPH generated by the Pentose Phosphate Pathway to reduce GSSG back into $2\text{ GSH}$, restoring the cell's antioxidant capacity.

• Erythrocyte Vulnerability:

  • Red blood cells lack mitochondria and rely entirely on G6PD and the Pentose Phosphate Pathway for NADPH synthesis.

  • G6PD Deficiency: Insufficient NADPH leads to an inability to maintain reduced GSH, resulting in oxidative denaturation of hemoglobin (Heinz bodies), cell membrane lipid peroxidation, and hemolytic anemia.

• Drug Metabolism:

  • NADPH is an obligate electron donor for Cytochrome P450 (CYP) mixed-function oxidases in the liver during phase I drug oxidation and xenobiotic detoxification.

Ethanol Metabolism Pathways

• $85-98\%$ of ingested ethanol is metabolized in the liver via two distinct enzymatic pathways.

• Major Cytosolic Pathway (Alcohol Dehydrogenase - ADH):

  1. $\text{Ethanol} + \text{NAD}^+ \xrightarrow{\text{ADH1}} \text{Acetaldehyde} + \text{NADH} + \text{H}^+$

  2. Acetaldehyde is a highly reactive, toxic intermediate responsible for acute toxicity, tissue damage, nausea, and vomiting.

  3. $\text{Acetaldehyde} + \text{NAD}^+ + \text{H}_2\text{O} \xrightarrow{\text{Mitochondrial ALDH2}} \text{Acetate} + \text{NADH} + \text{H}^+$

  4. Acetate enters circulation and is converted to Acetyl-CoA by Acetyl-CoA Synthetase in extrahepatic tissues (e.g., skeletal muscle) to produce ATP via the TCA cycle (yielding $\sim 13\text{ ATP}$ per ethanol).

  • Pharmacological Inhibitor (Disulfiram / Antabuse): Inhibits ALDH2, causing rapid, severe accumulation of acetaldehyde upon ethanol consumption. Disulfiram was developed around 1957-1958; early clinical doses were too high, causing severe nausea in patients consuming trace alcohol present in foods like ketchup.

• Inducible Microsomal Ethanol Oxidizing System (MEOS):

  • Occurs in the endoplasmic reticulum; mediated primarily by CYP2E1.

  • $\text{Ethanol} + \text{NADPH} + \text{H}^+ + \text{O}_2 \xrightarrow{\text{CYP2E1}} \text{Acetaldehyde} + \text{NADP}^+ + 2\,\text{H}_2\text{O}$

  • Requires NADPH consumption, yielding less net ATP ($\sim 8\text{ ATP}$ per ethanol). MEOS is upregulated in chronic heavy alcohol use.

Metabolic Pathology of Chronic Ethanol Ingestion

• Metabolizing ethanol via ADH and ALDH generates massive quantities of cytosolic and mitochondrial NADH, resulting in an abnormally elevated $\text{NADH}/\text{NAD}^+$ ratio that disrupts systemic metabolism.

• Inhibition of Fatty Acid $\beta$-Oxidation & Hepatic Steatosis:

  • Elevated NADH feedback-inhibits fatty acid $\beta$-oxidation.

  • Unoxidized fatty acids in hepatocytes are re-esterified into triacylglycerols.

  • Excess triacylglycerols overwhelm hepatic VLDL secretory capacity, accumulating within liver tissue to cause Hepatic Steatosis (Fatty Liver Disease) and hyperlipidemia.

• Inhibition of the TCA Cycle and Ketoacidosis:

  • High NADH inhibits Isocitrate Dehydrogenase and $\text{alpha}$-Ketoglutarate Dehydrogenase in the TCA cycle.

  • Acetyl-CoA accumulates and is diverted into ketogenesis, causing Ketoacidosis.

• Lactic Acidosis:

  • Elevated NADH shifts the reversible Lactate Dehydrogenase equilibrium toward lactate production: $\text{Pyruvate} + \text{NADH} + \text{H}^+ \rightarrow \text{Lactate} + \text{NAD}^+$.

  • Pyruvate accumulates (because Pyruvate Dehydrogenase Complex is inhibited by high NADH) and is converted into excess lactate, overwhelming hepatic uptake via the Cori cycle and causing Lactic Acidosis.

• Hypoglycemia:

  • High NADH forces Oxaloacetate (OAA) to reduce into Malate, depleting OAA reserves needed for gluconeogenesis.

  • The simultaneous depletion of pyruvate and OAA shuts down gluconeogenesis, causing severe Fasting Hypoglycemia.

Comprehensive Review Questions and Answers

• Question: What double-bond orientation is required for unsaturated fatty acids to proceed through $\beta$-oxidation?

  • Answer: Trans orientation (converted from cis by enoyl-CoA isomerase).

• Question: Exocytosis and release of insulin granules from pancreatic $\beta$ cells depends directly on an increase in the intracellular concentration of which ion?

  • Answer: Calcium ($Ca^{2+}$).

• Question: What central enzyme/protein kinase mediates intracellular signaling downstream of glucagon and cAMP?

  • Answer: Protein Kinase A (PKA).

• Question: During muscle exertion and the Cori cycle, lactate released into the blood is converted by the liver back into which immediate metabolic intermediate before forming glucose?

  • Answer: Pyruvate.

• Question: What molecule acts as a primary key allosteric regulator of Phosphofructokinase-1 (PFK-1)?

  • Answer: Magnesium-ATP ($Mg\text{-ATP}$).

• Question: What primary intracellular signaling pathway is activated downstream of the Insulin Receptor?

  • Answer: PI3K (Phosphoinositide 3-Kinase) signaling pathway.

• Question: Which specific glucose transporter isoform is insulin-sensitive and translocates to the plasma membrane in skeletal muscle and adipose tissue?

  • Answer: GLUT4.

• Question: Which specific solute carrier transporter functions as a dedicated fructose transporter?

  • Answer: GLUT5.

• Question: Which phase of the Pentose Phosphate Pathway yields the majority of cellular NADPH?

  • Answer: The Oxidative Phase (specifically G6PD and 6-Phosphogluconate Dehydrogenase reactions).

• Question: Which enzyme provides $100\%$ of the digestive capacity to hydrolyze dietary sucrose into glucose and fructose?

  • Answer: The sucrase domain of the Sucrase-Isomaltase Complex.

• Question: What sole enzyme is capable of cleaving Fructose-1-Phosphate in human fructose metabolism?

  • Answer: Aldolase B.